Coxibs supplement: Has CCJM sold out?

Article Type
Changed
Fri, 12/14/2018 - 06:26
Display Headline
Coxibs supplement: Has CCJM sold out?
Article PDF
Author and Disclosure Information

Marc C. Hochberg, MD, MPH
Guest editor of the coxib supplement, University of Maryland School of Medicine, Baltimore, MD

Issue
Cleveland Clinic Journal of Medicine - 69(7)
Publications
Page Number
568
Sections
Author and Disclosure Information

Marc C. Hochberg, MD, MPH
Guest editor of the coxib supplement, University of Maryland School of Medicine, Baltimore, MD

Author and Disclosure Information

Marc C. Hochberg, MD, MPH
Guest editor of the coxib supplement, University of Maryland School of Medicine, Baltimore, MD

Article PDF
Article PDF
Related Articles
Issue
Cleveland Clinic Journal of Medicine - 69(7)
Issue
Cleveland Clinic Journal of Medicine - 69(7)
Page Number
568
Page Number
568
Publications
Publications
Article Type
Display Headline
Coxibs supplement: Has CCJM sold out?
Display Headline
Coxibs supplement: Has CCJM sold out?
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

COX-2–selective inhibitors in the treatment of arthritis

Article Type
Changed
Fri, 12/07/2018 - 12:18
Display Headline
COX-2–selective inhibitors in the treatment of arthritis
Article PDF
Author and Disclosure Information

Thomas J. Schnitzer, MD, PhD
Office of Clinical Research and Training, Northwestern University School of Medicine, Chicago

Marc C. Hochberg, MD, MPH
Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore

Correspondence: Thomas J. Schnitzer, MD, PhD, Professor of Medicine, Director, Office of Clinical Research and Training, Northwestern University School of Medicine, 710 North Lake Shore Drive, 10th Floor, Chicago, IL 60611; e-mail: [email protected]

Dr. Schnitzer has indicated that he has received clinical research support from Merck & Co., Inc., Novartis, Ortho-McNeil, McNeil Pharmaceuticals, Pharmacia, and Wyeth-Ayerst; has been a consultant for AstraZeneca, GlaxoSmithKline, McNeil Pharmaceuticals, Merck & Co., Inc., Novartis, Ortho-McNeil, and Wyeth-Ayerst; and is on the speakers’ bureaus of Merck & Co., Inc., Ortho-McNeil, and Wyeth-Ayerst.

Dr. Hochberg has indicated that he has received grant or research support from Merck & Co., Inc., and has been a consultant for Merck & Co., Inc., and Novartis.

Publications
Page Number
SI20-SI30
Author and Disclosure Information

Thomas J. Schnitzer, MD, PhD
Office of Clinical Research and Training, Northwestern University School of Medicine, Chicago

Marc C. Hochberg, MD, MPH
Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore

Correspondence: Thomas J. Schnitzer, MD, PhD, Professor of Medicine, Director, Office of Clinical Research and Training, Northwestern University School of Medicine, 710 North Lake Shore Drive, 10th Floor, Chicago, IL 60611; e-mail: [email protected]

Dr. Schnitzer has indicated that he has received clinical research support from Merck & Co., Inc., Novartis, Ortho-McNeil, McNeil Pharmaceuticals, Pharmacia, and Wyeth-Ayerst; has been a consultant for AstraZeneca, GlaxoSmithKline, McNeil Pharmaceuticals, Merck & Co., Inc., Novartis, Ortho-McNeil, and Wyeth-Ayerst; and is on the speakers’ bureaus of Merck & Co., Inc., Ortho-McNeil, and Wyeth-Ayerst.

Dr. Hochberg has indicated that he has received grant or research support from Merck & Co., Inc., and has been a consultant for Merck & Co., Inc., and Novartis.

Author and Disclosure Information

Thomas J. Schnitzer, MD, PhD
Office of Clinical Research and Training, Northwestern University School of Medicine, Chicago

Marc C. Hochberg, MD, MPH
Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore

Correspondence: Thomas J. Schnitzer, MD, PhD, Professor of Medicine, Director, Office of Clinical Research and Training, Northwestern University School of Medicine, 710 North Lake Shore Drive, 10th Floor, Chicago, IL 60611; e-mail: [email protected]

Dr. Schnitzer has indicated that he has received clinical research support from Merck & Co., Inc., Novartis, Ortho-McNeil, McNeil Pharmaceuticals, Pharmacia, and Wyeth-Ayerst; has been a consultant for AstraZeneca, GlaxoSmithKline, McNeil Pharmaceuticals, Merck & Co., Inc., Novartis, Ortho-McNeil, and Wyeth-Ayerst; and is on the speakers’ bureaus of Merck & Co., Inc., Ortho-McNeil, and Wyeth-Ayerst.

Dr. Hochberg has indicated that he has received grant or research support from Merck & Co., Inc., and has been a consultant for Merck & Co., Inc., and Novartis.

Article PDF
Article PDF
Page Number
SI20-SI30
Page Number
SI20-SI30
Publications
Publications
Article Type
Display Headline
COX-2–selective inhibitors in the treatment of arthritis
Display Headline
COX-2–selective inhibitors in the treatment of arthritis
Citation Override
Cleveland Clinic Journal of Medicine 2002 April;69(suppl 1):SI20-SI30
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media